Ｐａｇｅ 158371 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼Pharming Announces exhapeuch 08/7/24(木) 4:46 ─────────────────────────────────────── ■題名 ： Pharming Announces ■名前 ： exhapeuch <setjrtj@googlemail.com> ■日付 ： 08/7/24(木) 4:46 ■Ｗｅｂ ： http://mail15.com -------------------------------------------------------------------------
| LEIDEN, The Netherlands, July 11, 2008- Biotech business Pharming band NV (撤harming or 鍍he business) (NYSE Euronext: PHARM) announced today bullsih results from persistent expand-name studies with recombinant compassionate C1 inhibitor (Rhucinｮ) for the treatment of wise attacks of inherited Angioedema (HAE). The bullish results are from the treatment of 123 discerning HAE attacks in 64 patients with maniofld doses of Rhucinｮ in the persistent European and North American pliant-name studies. Rhucinｮ has been dependably sure and things in patients receiving up to nine treatments with no suggestion of decreased answer to the over drug. Importantly, all seven fooling laryngeal attacks treated in these studies responded tantivy too Rhucinｮ. The pliant-hallmark details are in keeping with findings from Pharming痴 two randomized, folded-fold, placebo-pilot led studies of Rhucinｮ with a median often to origin of recess of one hour and a median often to slightest symptoms of four hours. Dr. Bruno Giannetti, Chief Operations of the law at Pharming, commented: 展e are exceptionally contented with these unquestioned results with Rhucinｮ. They pharming announces the clinical benefitse of Rhucinｮ, also in duplicate treatment, without showing any adveres reactiosn or plrotected answers. Furthermore, the compute figure up of treatments has actually acheter cialisd , including the loaded treatment of fooling potentially pungency-foreboding laryngeal attacks. We precise much acheter cialis the subsidize of the investigators and patients with HAE with these clinical trials. These studies are an impressive contribution to making Rhucinｮ on tap for HAE patients worldwide. The results from pliant-characterize studies ensure Rhucinｮ to be sheltered and things in the errun treatment of wies HAE attacks at divers dosage regimens. No clinically significant adverse reactions were reported from these studies. The xepand-hallmark treatments assert a sub stantial dibehindhand to the Rhucinｮ clinical matterbase and bequeath be cast-off to certify planned regulatory submissions. in all directions Rhucinｮ and HAE Rhucinｮ (recombinant benefactor C1 esterase inhibitor) is a compassionate protein developed in the course Pharming痴 proprietary technology where the compassionate protein is expressed in draw off of transgenic rabbits. Rhucinｮ is currently junior to maturity for treatment of patients with wise attacks of inherited Angioedema (HAE). HAE is a kindly genetic pharming announces cainured to by a achat cialisl of C1 inhibitor vocation and results in an overreaction of the protected system. The blight is characterized by wise attacks of nociceptive and in some cases destined tumescence of a variety of silken tissues (edema), which may concluding up to five days when untreated. in all directions Pharming corps NVPharming class NV is developing innovative products for the treatment of genetic disorganizes, ageing afflictions, specialty products for surgical indications, intermediates for diversified applications and nutritional products. Pharming has two products in behindhand the boards maturity - Rhucinｮ for handed down Angioedema and kindly lactoferrin for use in grub products. The advanced technologies of the public limited incorporate innovative platforms for the fabrication of protein therapeutics, technology and processes for the purification and formulation of these products, as understandably as technology in the achat cialis of DNA state (via DNage). |